vs
PUMA BIOTECHNOLOGY, INC.（PBYI）与P10, Inc.（PX）财务数据对比。点击上方公司名可切换其他公司
P10, Inc.的季度营收约是PUMA BIOTECHNOLOGY, INC.的1.1倍（$81.0M vs $75.5M），PUMA BIOTECHNOLOGY, INC.同比增速更快（27.7% vs -4.7%），P10, Inc.自由现金流更多（$18.1M vs $14.4M），过去两年PUMA BIOTECHNOLOGY, INC.的营收复合增速更高（31.3% vs 10.7%）
彪马生物技术是一家公开上市的生物制药企业，总部位于美国加利福尼亚州洛杉矶，专注于创新药物研发相关业务，在生物制药领域开展研发与商业化运营。
P10, Inc.是一家全球另类资产管理公司，提供涵盖私募股权、私募信贷、实物资产、风险投资的多元化投资解决方案，主要服务北美、欧洲、亚太市场的养老基金、捐赠基金、基金会及高净值个人等客户群体。
PBYI vs PX — 直观对比
营收规模更大
PX
是对方的1.1倍
$75.5M
营收增速更快
PBYI
高出32.4%
-4.7%
自由现金流更多
PX
多$3.7M
$14.4M
两年增速更快
PBYI
近两年复合增速
10.7%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $75.5M | $81.0M |
| 净利润 | — | $9.5M |
| 毛利率 | 69.3% | — |
| 营业利润率 | 22.7% | 31.9% |
| 净利率 | — | 11.7% |
| 营收同比 | 27.7% | -4.7% |
| 净利润同比 | — | 79.0% |
| 每股收益（稀释后） | $0.26 | $0.08 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收PBYIPX
| Q4 25 | $75.5M | $81.0M | ||
| Q3 25 | $54.5M | $75.9M | ||
| Q2 25 | $52.4M | $72.7M | ||
| Q1 25 | $46.0M | $67.7M | ||
| Q4 24 | $59.1M | $85.0M | ||
| Q3 24 | $80.5M | $74.2M | ||
| Q2 24 | $47.1M | $71.1M | ||
| Q1 24 | $43.8M | $66.1M |
净利润PBYIPX
| Q4 25 | — | $9.5M | ||
| Q3 25 | $8.8M | $2.1M | ||
| Q2 25 | $5.9M | $3.4M | ||
| Q1 25 | $3.0M | $4.5M | ||
| Q4 24 | — | $5.3M | ||
| Q3 24 | $20.3M | $1.4M | ||
| Q2 24 | $-4.5M | $7.0M | ||
| Q1 24 | $-4.8M | $5.0M |
毛利率PBYIPX
| Q4 25 | 69.3% | — | ||
| Q3 25 | 77.7% | — | ||
| Q2 25 | 76.5% | — | ||
| Q1 25 | 77.1% | — | ||
| Q4 24 | 76.4% | — | ||
| Q3 24 | 63.9% | — | ||
| Q2 24 | 77.4% | — | ||
| Q1 24 | 75.5% | — |
营业利润率PBYIPX
| Q4 25 | 22.7% | 31.9% | ||
| Q3 25 | 17.6% | 14.1% | ||
| Q2 25 | 12.7% | 24.4% | ||
| Q1 25 | 8.7% | 16.6% | ||
| Q4 24 | 22.6% | 26.9% | ||
| Q3 24 | 27.4% | 11.9% | ||
| Q2 24 | -4.6% | 23.7% | ||
| Q1 24 | -5.3% | 18.3% |
净利率PBYIPX
| Q4 25 | — | 11.7% | ||
| Q3 25 | 16.2% | 2.8% | ||
| Q2 25 | 11.2% | 4.7% | ||
| Q1 25 | 6.5% | 6.7% | ||
| Q4 24 | — | 6.2% | ||
| Q3 24 | 25.2% | 1.9% | ||
| Q2 24 | -9.6% | 9.8% | ||
| Q1 24 | -11.0% | 7.6% |
每股收益（稀释后）PBYIPX
| Q4 25 | $0.26 | $0.08 | ||
| Q3 25 | $0.17 | $0.02 | ||
| Q2 25 | $0.12 | $0.03 | ||
| Q1 25 | $0.06 | $0.04 | ||
| Q4 24 | $0.40 | $0.05 | ||
| Q3 24 | $0.41 | $0.01 | ||
| Q2 24 | $-0.09 | $0.06 | ||
| Q1 24 | $-0.10 | $0.04 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $97.5M | $28.2M |
| 总债务越低越好 | $22.7M | $373.2M |
| 股东权益账面价值 | $130.3M | $403.5M |
| 总资产 | $216.3M | $928.3M |
| 负债/权益比越低杠杆越低 | 0.17× | 0.93× |
8季度趋势，按日历期对齐
现金及短期投资PBYIPX
| Q4 25 | $97.5M | $28.2M | ||
| Q3 25 | $94.4M | $40.0M | ||
| Q2 25 | $96.0M | $33.4M | ||
| Q1 25 | $93.2M | $74.4M | ||
| Q4 24 | $101.0M | $67.5M | ||
| Q3 24 | $96.7M | $61.5M | ||
| Q2 24 | $96.8M | $31.2M | ||
| Q1 24 | $107.2M | $29.0M |
总债务PBYIPX
| Q4 25 | $22.7M | $373.2M | ||
| Q3 25 | $34.0M | $393.4M | ||
| Q2 25 | $45.3M | $373.0M | ||
| Q1 25 | $56.7M | $357.2M | ||
| Q4 24 | $68.0M | $319.8M | ||
| Q3 24 | $79.3M | $319.4M | ||
| Q2 24 | $90.7M | $300.6M | ||
| Q1 24 | $102.0M | $314.0M |
股东权益PBYIPX
| Q4 25 | $130.3M | $403.5M | ||
| Q3 25 | $115.3M | $396.8M | ||
| Q2 25 | $104.7M | $388.9M | ||
| Q1 25 | $97.1M | $374.3M | ||
| Q4 24 | $92.1M | $386.9M | ||
| Q3 24 | $71.1M | $394.1M | ||
| Q2 24 | $48.5M | $396.9M | ||
| Q1 24 | $51.0M | $400.1M |
总资产PBYIPX
| Q4 25 | $216.3M | $928.3M | ||
| Q3 25 | $202.9M | $936.0M | ||
| Q2 25 | $194.9M | $932.2M | ||
| Q1 25 | $196.2M | $877.4M | ||
| Q4 24 | $213.3M | $869.3M | ||
| Q3 24 | $220.7M | $857.0M | ||
| Q2 24 | $205.0M | $823.2M | ||
| Q1 24 | $214.1M | $832.8M |
负债/权益比PBYIPX
| Q4 25 | 0.17× | 0.93× | ||
| Q3 25 | 0.30× | 0.99× | ||
| Q2 25 | 0.43× | 0.96× | ||
| Q1 25 | 0.58× | 0.95× | ||
| Q4 24 | 0.74× | 0.83× | ||
| Q3 24 | 1.12× | 0.81× | ||
| Q2 24 | 1.87× | 0.76× | ||
| Q1 24 | 2.00× | 0.78× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $14.4M | $23.0M |
| 自由现金流经营现金流 - 资本支出 | $14.4M | $18.1M |
| 自由现金流率自由现金流/营收 | 19.1% | 22.3% |
| 资本支出强度资本支出/营收 | 0.0% | 6.0% |
| 现金转化率经营现金流/净利润 | — | 2.43× |
| 过去12个月自由现金流最近4个季度 | $41.7M | $14.1M |
8季度趋势，按日历期对齐
经营现金流PBYIPX
| Q4 25 | $14.4M | $23.0M | ||
| Q3 25 | $9.7M | $-8.6M | ||
| Q2 25 | $14.1M | $13.4M | ||
| Q1 25 | $3.6M | $-4.7M | ||
| Q4 24 | $15.6M | $101.0M | ||
| Q3 24 | $11.0M | $27.5M | ||
| Q2 24 | $1.0M | $34.8M | ||
| Q1 24 | $11.2M | $11.0M |
自由现金流PBYIPX
| Q4 25 | $14.4M | $18.1M | ||
| Q3 25 | $9.7M | $-9.5M | ||
| Q2 25 | $14.1M | $11.6M | ||
| Q1 25 | $3.6M | $-6.0M | ||
| Q4 24 | $15.6M | $96.6M | ||
| Q3 24 | $11.0M | $25.2M | ||
| Q2 24 | $1.0M | $33.9M | ||
| Q1 24 | — | $10.7M |
自由现金流率PBYIPX
| Q4 25 | 19.1% | 22.3% | ||
| Q3 25 | 17.7% | -12.6% | ||
| Q2 25 | 26.8% | 15.9% | ||
| Q1 25 | 7.7% | -8.9% | ||
| Q4 24 | 26.4% | 113.6% | ||
| Q3 24 | 13.7% | 34.0% | ||
| Q2 24 | 2.1% | 47.7% | ||
| Q1 24 | — | 16.2% |
资本支出强度PBYIPX
| Q4 25 | 0.0% | 6.0% | ||
| Q3 25 | 0.0% | 1.2% | ||
| Q2 25 | 0.0% | 2.5% | ||
| Q1 25 | 0.1% | 1.9% | ||
| Q4 24 | 0.0% | 5.2% | ||
| Q3 24 | 0.0% | 3.0% | ||
| Q2 24 | 0.0% | 1.3% | ||
| Q1 24 | 0.0% | 0.4% |
现金转化率PBYIPX
| Q4 25 | — | 2.43× | ||
| Q3 25 | 1.10× | -4.01× | ||
| Q2 25 | 2.41× | 3.96× | ||
| Q1 25 | 1.21× | -1.05× | ||
| Q4 24 | — | 19.12× | ||
| Q3 24 | 0.54× | 19.54× | ||
| Q2 24 | — | 4.98× | ||
| Q1 24 | — | 2.18× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
PBYI
暂无分部数据
PX
| Management Fees | $78.1M | 96% |
| Advisory Fees | $1.8M | 2% |
